Breast Cancer | Specialty

Targeted Therapies Continue to Shape Future Breast Cancer Paradigm

March 5th 2021

With the identification of numerous molecular abnormalities that can affect treatment and the course of disease in patients with breast cancer, it’s become understood that genetic profiling can define clinical trial eligibility, the presence or absence of aberrations help to drive treatment decisions, and variants can be predictive for response or resistance.

Local Management in Stage IV Breast Cancer Requires More Refinement

March 5th 2021

Although there is evidence to suggest that surgery with or without radiation therapy can be utilized in some patients with stage IV breast cancer who have experienced locoregional progression or symptoms to some success with regard to locoregional disease control, most patients will not achieve a survival benefit.

Adjuvant CDK4/6 Inhibition Shows Potential in Early HR+/HER2- Breast Cancer, But More Data Are Needed

March 5th 2021

CDK4/6 inhibitors plus aromatase inhibitors have shown benefit as frontline treatment for patients with hormone receptor–positive, HER2-negative advanced breast cancer, but more data are needed to determine their role as adjuvant therapy before they are adopted into standard practice for patients with early-stage disease.

Decision Factors for SubQ Therapy and Unmet Needs

March 5th 2021

Rationale for Ovarian Suppression in HR+ Breast Cancer

March 5th 2021

During a discussion regarding data demonstrated by the RxPONDER trial in HR-positive breast cancer, breast oncologists consider when ovarian suppression is most appropriate and for whom.

Results of RxPONDER in HR+ Breast Cancer

March 5th 2021

Dr Andrew Seidman reacts to outcomes of the RxPONDER trial of chemotherapy use in women with HR-positive breast cancer at low risk of recurrence.

Dr. Brufsky on the Role of Neoadjuvant Chemotherapy in TNBC

March 5th 2021

Adam M. Brufsky, MD, PhD, discusses the role of neoadjuvant chemotherapy in triple-negative breast cancer.

Dr. Borgen on Eliminating Opioid Use in Breast Cancer

March 5th 2021

Patrick I. Borgen, MD, discusses eliminating the use of opioids in patients with breast cancer.

New Indications in HER2+ Breast Cancer Spark Discussions on Selection, Safety, and Sequencing

March 4th 2021

The KATHERINE, FeDeriCa, DESTINY-Breast01, and HER2CLIMB trials have changed practice for patients with HER2-positive breast cancer for the better.

Waisman Walks Through Sequencing Strategy in Metastatic HER2-Positive Breast Cancer

March 4th 2021

James R. Waisman, MD, shares his process for matching patients with the right treatment in the metastatic setting and areas for future exploration.

Dr. Wei on Benefits of Subcutaneous Pertuzumab/Trastuzumab in HER2+ Early Breast Cancer

March 3rd 2021

Mei Wei, MD, discusses the benefits of subcutaneous administration of pertuzumab and trastuzumab in patients with HER2-positive early breast cancer.

Antibody-Drug Conjugates, TKIs Drive Improved Outcomes in HER2+ Breast Cancer

March 3rd 2021

The practice-changing treatment regimens that were evaluated in the pivotal KATHERINE, HER2CLIMB, and DESTINY-Breast01 trials in women with HER2-positive breast cancer are pushing the needle forward in making this breast cancer subtype a chronic disease.

Dr. Bardia on Efficacy With Atezolizumab Combos in Metastatic TNBC

March 2nd 2021

Aditya Bardia, MD, MPH, discusses efficacy with atezolizumab combinations in patients with metastatic triple-negative breast cancer.

Dr. Wei on the Efficacy of Trastuzumab Deruxtecan in HER2+ Metastatic Breast Cancer

March 1st 2021

Mei Wei, MD, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer, as demonstrated in the DESTINY-Breast01 trial.

FDA Issues Complete Response Letter for Oral Paclitaxel Plus Encequidar for Metastatic Breast Cancer

March 1st 2021

The FDA has issued a complete response letter to Athenex, Inc. stating that it will not, at this time, approve the new drug application for oral paclitaxel in combination with encequidar for the treatment of patients with metastatic breast cancer.

Phase 3 FeDeriCa and PHranceSCa Trial Overviews

February 26th 2021

Novel Agents for Late-Stage HER2+ MBC

February 26th 2021

Early-Stage HR+ Breast Cancer: Treatment Options

February 26th 2021

Risk of Recurrence in Early-Stage HR+ Breast Cancer

February 26th 2021

Oral Taxanes Open the Door for New Standards in Metastatic Breast Cancer

February 22nd 2021

Sara A. Hurvitz, MD, discusses the potential integration of oral taxanes into the treatment paradigm of patients with metastatic breast cancer.